Join Growin Stock Community!

祥翊6676.TW Overview

TW StockBiotech. & Medical
(No presentation for 6676)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

祥翊（6676）Overall Performance

祥翊（6676）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

祥翊（6676） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

祥翊（6676）Key Information

祥翊（6676）Profile

Sunny Pharmtech Inc. engages in the research, development, production, and sale of drug substances and products, and active pharmaceutical ingredients in Taiwan and internationally. Its products portfolio include lidocaine ointment that can be used as an anesthetic lubricant for intubation, which temporarily relieves pain associated with minor burns, sunburn, skin abrasions, and insect bites; cyanocobalamin injection for use in vitamin B12 deficiency and pernicious anemia caused by malabsorption; nitrofurantoin capsules for urinary tract infection; aminocaproic acid tablets for blood diseases, as well as for hyper-proteolytic enzymes; and carboprost tromethamine injection for therapeutic abortion and postpartum hemorrhage. The company was founded in 1994 and is based in Taoyuan, Taiwan.

祥翊（6676）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.67
PB Ratio
2.95
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
61.34%
Net Margin
-46.29%
Revenue Growth (YoY)
19.72%
Profit Growth (YoY)
36.76%
3-Year Revenue Growth
-4.27%
3-Year Profit Growth
-24.20%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.67
PB Ratio
2.95
Price-to-FCF
-
Gross Margin
61.34%
Net Margin
-46.29%
Revenue Growth (YoY)
19.72%
Profit Growth (YoY)
36.76%
3-Year Revenue Growth
-4.27%
3-Year Profit Growth
-24.20%
default symbol

6676

祥翊

17.75D

-0.56%

(-0.01)

  • When is 6676's latest earnings report released?

    The most recent financial report for 祥翊 (6676) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6676's short-term business performance and financial health. For the latest updates on 6676's earnings releases, visit this page regularly.

  • How much cash does 6676 have?

    At the end of the period, 祥翊 (6676) held Total Cash and Cash Equivalents of 77.93M, accounting for 0.05 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6676 go with three margins increasing?

    In the latest report, 祥翊 (6676) did not achieve the “three margins increasing” benchmark, with a gross margin of 42.55%%, operating margin of -131.58%%, and net margin of -144.52%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6676's profit trajectory and future growth potential.